Amgen's shares took a significant hit following disappointing news from a competitor.
Amgen Inc. (NASDAQ: AMGN) experienced a steep decline of 10.08% in its stock price during yesterday's trading session, closing at CA$393.17. This drop was primarily influenced by adverse developments related to a competitor's drug trial.
Advertisement
Investor takeaway: Investors reacted swiftly to Novartis' recent announcement regarding its cholesterol drug, which failed to meet expectations in a late-stage trial. This news raised concerns about Amgen's similar drug in development, leading to a sell-off.
10.08% Decline in Amgen's Stock
This significant drop reflects investor fears and market reactions to competitive pressures in the biopharma sector.
Bull case
Despite the recent setback, some analysts think the market may have overreacted. They believe Amgen could rebound as it continues to develop its drug pipeline.
Bear case
The failure of Novartis' drug might signal broader challenges in the cardiovascular drug market. This raises concerns for Amgen's future, and if investor sentiment stays negative, further declines could follow.
Advertisement
Market Reaction to Novartis' Drug Trial Failure
The catalyst for Amgen's significant stock drop was Novartis' announcement that its cholesterol drug did not succeed in a critical late-stage trial aimed at cardiovascular outcomes. This news sent shockwaves through the biopharma sector, with investors fearing that Amgen's similar drug could face similar challenges.
Broader Market Trends Impacting Amgen
Amgen's decline also mirrored a broader downturn in the stock market, where inflation concerns and rising oil prices contributed to a negative trading environment. The Nasdaq Composite fell 0.3%, reflecting a general risk-off sentiment among investors, further exacerbating the situation for Amgen.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
